Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ogsiveo in Desmoid Tumors
NCT01981551Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Oct 2013
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rilzabrutinib in desmoid tumor, sponsored by National Cancer Institute. Primary endpoint: Objective Response Rate at 20 months. Started Oct 2013; status: completed.
02
Drugs
rilzabrutinib
03
Conditions
desmoid tumor
Beyond the preview
Go deeper on NCT01981551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01981551.